Eli Lilly maintains lead in obesity drug race as AstraZeneca joins the competition
TL;DR Summary
AstraZeneca has entered the obesity drug market, but Eli Lilly remains the preferred choice for investors.
Topics:business#astrazeneca#competition#eli-lilly#obesity-drug#pharmaceuticals#weight-loss-drug-market
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
85%
108 → 16 words
Want the full story? Read the original article
Read on CNBC